SY001 / SynRx Therap - LARVOL DELTA

SY001 Targets Mesothelin in a Single-arm, Dose-increasing Setting in Subjects With Advanced Solid Tumors (clinicaltrials.gov) - P=N/A | N=2 | Recruiting | Sponsor: Cell Origin Biotech (Hangzhou) Co., Ltd. | Trial completion date: Apr 2025 ➔ Dec 2027 | Trial primary completion date: Apr 2025 ➔ Dec 2026

Trial completion date • Trial primary completion date • Oncology • Ovarian Cancer • Solid Tumor